Brazil Oral Anti-Diabetic Drug Market Size
|Base Year For Estimation||2022|
|Forecast Data Period||2023 - 2028|
|Historical Data Period||2018 - 2021|
|CAGR||> 3.40 %|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Brazil Oral Anti-Diabetic Drug Market Analysis
The Brazil Oral Anti-Diabetic Drug Market is expected to register a CAGR of more than 3% during the forecast period, with revenue of USD 13 billion in the current year.
The COVID-19 pandemic caused early fatalities during the first year of its existence, primarily in older people. The majority of COVID-19 fatalities were caused by the co-existence of two or more chronic diseases in the same person. Numerous studies have established the link between long-term conditions, including diabetes, and unfavorable outcomes in COVID-19 patients. Compared to healthy persons, those with diabetes are more likely to experience significant complications. During COVID-19, the makers of diabetes pharmaceuticals took special care to ensure that diabetic patients received their meds with the assistance of local governments. Pharmaceuticals known as diabetic medications were created to stabilize and regulate blood glucose levels in diabetics. Diabetes patients infected with SARS-CoV-2 during the COVID-19 pandemic may be treated with diabetic medications. The relevance of diabetes treatment medications has been highlighted by the high incidence of diabetes among those hospitalized with COVID-19 infection and the realization that better glycemic management may improve outcomes and shorten hospital stays in COVID-19 patients.
One in ten Brazilian people, or 15.7 million individuals, or roughly 10.5% of the population, have diabetes, according to the IDF Diabetes Atlas 2021. Brazil has the third-highest global diabetes-related health expenditure, with a cost of 42.9 billion USD. Additionally, 18.9% of adults, or 18 million people, have impaired glucose tolerance, which puts them at a greater risk of becoming type 2 diabetes. In Brazil, 32% of diabetics do not have a diagnosis. Only 25% of Brazilians, according to further data on glycaemic management, achieved the treatment target of having an HbA1c of less than 7% prior to the pandemic, as advised by the Brazilian Diabetes Society (SBD).
Diabetes patients run the danger of significant and even fatal consequences like heart attack, stroke, kidney failure, blindness, and lower limb amputation when their condition is undiagnosed or not appropriately controlled. These have a negative impact on quality of life, increase healthcare spending, and make access to treatment more important. In order to combat risk factors like obesity and emerging pandemic threats, Brazil has implemented a number of reforms over the years to improve the distribution of doctors, create new types of service organizations, introduce new financing models, and implement a variety of quality improvement initiatives and policy frameworks. This also shows areas where improvements in the way diabetes treatment is provided may be expanded and continued.
Brazil Oral Anti-Diabetic Drug Market Trends
Sulfonylurea Segment Occupied the Highest Market Share in the Brazil Oral Anti-Diabetic Drugs Market in the current year.
In terms of revenue, the sulfonylurea segment is anticipated to lead the Brazil Oral Anti-Diabetic Drugs Market and post a CAGR of over 1% during the forecast year.
Oral anti-diabetic medications have been made available globally and are advised for usage when type 2 diabetes therapy needs to be escalated along with lifestyle modification. Due to the wide variety of effectiveness, safety, and modes of action that oral medicines have, they are frequently the first treatments employed in the treatment of type 2 diabetes. Diabetes patients can minimize their risk of complications and maintain control of their illness with the use of anti-diabetic medications. For the rest of their lives, people with diabetes may need to take anti-diabetic medications to manage their blood sugar levels and prevent hypo and hyperglycemia. Oral anti-diabetic medications have higher acceptability than insulin, which improves adherence to therapy. They also have the advantages of easier control and cheaper cost. IDF asserts that a number of socioeconomic, demographic, environmental, and genetic factors, including urbanization, aging populations, declining levels of physical activity, and rising rates of overweight and obesity, are to blame for Brazil's type 2 diabetes epidemic. In Brazil, diabetes is becoming more common among people of all ages. Due to its high incidence and associated rising cost burdens on individuals, healthcare systems, and governments, diabetes mellitus has drawn a lot of attention. The Brazilian government's many measures are anticipated to fuel the market's expansion. In order to guarantee affordable medicine pricing, the government has cooperated with various private businesses to make use of its supply chain (production, distribution, and merchants).
Sulfonylureas reduce glycated hemoglobin A1C (HbA1c) by 1% to 1.25% and have comparable effectiveness. Due to their low cost, second-generation sulfonylureas are among the most popular anti-diabetic drugs. Today, doctors seldom ever recommend first-generation sulfonylureas. For older individuals and those with renal or hepatic impairment, sulfonylureas are not recommended. Sulfonylureas can be used with any other oral diabetes medicine, with the exception of meglitinides (nateglinide and repaglinide), for type 2 diabetes patients.
To understand key trends, Download Sample Report
The increasing Diabetes Population in Brazil is driving the market.
Diabetes is a serious health issue that presents one of the most amazing difficulties to Brazilian healthcare systems. The development of novel medications to provide diabetic patients with more treatment choices has been driven by the disease's increasing incidence, prevalence, and progressive nature. Some of the key prospects for the participants in the diabetes medications market include the introduction of several new products, expanding international research partnerships for technological progress, and raising public awareness of diabetes. The Brazilian government's many measures are anticipated to fuel the market's expansion. To assure affordable medicine pricing, the Brazilian Federal Government collaborated with various private businesses to use their supply chain (production, distribution, and retailing).
The level of support for people with diabetes has been steadily rising under Brazil's public health system (Sistema nico de Sade; SUS). In Brazil, SUS continued to be the primary source for obtaining oral anti-diabetic medications, funding more than 70% of them in the nation when taking into account Health Unit Pharmacies and Popular Pharmacies, demonstrating the significance of public pharmaceutical policies in ensuring the Brazilian population's access to medications and in lowering inequities in the nation. However, the shift of consumers from SUS Health Units to Popular Pharmacies shows that Primary Health treatment's role in the administration of oral anti-diabetic medications may be lessened, damaging the relationship and the continuity of treatment. The health system has to be reorganized due to the rise in chronic illnesses, which calls for investments in research, surveillance, NCD prevention, and the promotion of healthy lifestyles. The Brazilian Ministry of Health published the Strategic Action Plan to Tackle NCDs in Brazil, 2011-2022, which calls for the expansion of free access to medications and other health products. It also aims to monitor access to essential health services, including medication, as a crucial part of NCD surveillance. It is therefore anticipated to drive the category expansion during the forecast period because of the aforementioned factors.
Brazil Oral Anti-Diabetic Drug Industry Overview
Brazil's oral anti-diabetes drug market is semi-consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.
Brazil Oral Anti-Diabetic Drug Market Leaders
*Disclaimer: Major Players sorted in no particular order
Brazil Oral Anti-Diabetic Drug Market News
- Mar 2022: Oramed announced that ORMD-0801 (a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule with the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets.
- Feb 2022: Eurofarma launched Suganon (evogliptin) in Latin America, an innovative therapy for type 2 diabetes patients. Suganon (evogliptin) is a new DPP-4 enzyme inhibitor, which features the benefits of offering convenient dosing, as well as having a low potential for interaction with other medications, ensuring greater ease and safety for prescribers and type 2 diabetes patients.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Oral Anti-diabetic drugs
5.1.2 Alpha-Glucosidase Inhibitors
220.127.116.11 Alpha-Glucosidase Inhibitors
5.1.3 Dopamine D2 receptor agonist
5.1.4 SGLT-2 inhibitors
18.104.22.168 Invokana (Canagliflozin)
22.214.171.124 Jardiance (Empagliflozin)
126.96.36.199 Farxiga/Forxiga (Dapagliflozin)
188.8.131.52 Suglat (Ipragliflozin)
5.1.5 DPP-4 inhibitors
184.108.40.206 Onglyza (Saxagliptin)
220.127.116.11 Tradjenta (Linagliptin)
18.104.22.168 Galvus (Vildagliptin)
6. MARKET INDICATORS
6.1 Type-1 Diabetic Population
6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.2 Novo Nordisk
7.1.4 Eli Lilly
7.1.5 Janssen Pharmaceuticals
7.1.7 Boehringer Ingelheim
7.1.8 Merck And Co.
7.1.10 Bristol Myers Squibb
- *List Not Exhaustive
7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The Brazil Oral Anti-Diabetic Drug Market is studied from 2018 - 2028.
What is the growth rate of Brazil Oral Anti-Diabetic Drug Market?
The Brazil Oral Anti-Diabetic Drug Market is growing at a CAGR of >3.4% over the next 5 years.
What is Brazil Oral Anti-Diabetic Drug Market size in 2018?
The Brazil Oral Anti-Diabetic Drug Market is valued at 13 Billion USD in 2018.
What is Brazil Oral Anti-Diabetic Drug Market size in 2028?
The Brazil Oral Anti-Diabetic Drug Market is valued at 16 Billion USD in 2028.
Who are the key players in Brazil Oral Anti-Diabetic Drug Market?
Astrazeneca, Eli Lilly, Sanofi, Pfizer, Novartis are the major companies operating in Brazil Oral Anti-Diabetic Drug Market.
Brazil Oral Anti-Diabetic Drug Industry Report
Statistics for the 2023 Brazil Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Brazil Oral Anti-Diabetic Drug analysis includes a market forecast outlook to for 2023 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.